Back to search results
NCT02437526

Analytic Treatment Interruption (ATI) to Assess HIV Cure

Enrolling by Invitation
NAAges 18+InterventionalDiagnostic
Mayo Clinic
~10 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:Analytic treatment interruption

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to virologic rebound
Measured over 38 weeks

Conditions

HIV

Explore related trials

HIV InfectionHIV-1 proviral DNAHIV Infection

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Andrew Badley, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
HIV-1 infected with the potential to have been cured of infection in the course of routine clinical care in the opinion of the treating physician and study team
Have an undetectable plasma HIV-1 RNA and undetectable proviral DNA on suppressive antiretroviral therapy on at least two consecutive measures for at least 6 months
Able and willing to either abstain from sexual activity or use barrier contraceptives during the ATI
Negative serum β-HCG pregnancy test in women with childbearing potential
Have the ability to give appropriate informed consent.

Exclusion

Women who are pregnant or nursing
Women who can become pregnant who are unable or unwilling to use both barrier and pharmacologic contraceptives during the ATI
Previous or current infections that are at high risk of reactivating with immune suppression, in whom there are no effective antimicrobial prophylaxis options
Advanced cardiopulmonary or liver disease
History of untreated solid or hematologic malignancies
Evidence of active viral replication in patients co-infected with Hepatitis B virus (HBV). Treatment should be provided to suppress HBV replication with agents that do not have activity against HIV (ie entecavir) prior to consideration for ATI.
Evidence of viral replication with Hepatitis C virus (HCV), together with evidence of any hepatic fibrosis or inflammation. Such patients should be offered HCV treatment first.

What this trial measures

  • Time to virologic rebound38 weeks